Immune Thrombocytopenia
Chronic immune thrombocytopenia (ITP) is the main therapeutic area reflected in Kedrion S.p.A.’s clinical research activity, with attention on adult patients living with persistent low platelet counts.
- Platelet count recovery
- Bleeding risk reduction
- Adult ITP management
The sponsor’s research interest centers on immunoglobulin-based treatment in autoimmune haematology, particularly in the setting of thrombocytopenia.
Immunology and Immune Modulation
Kedrion’s funded study activity is closely linked to therapies that influence the immune system and help restore platelet levels in immune-mediated disease.
- Human normal immunoglobulin
- Immune-mediated platelet destruction
- Antibody-based therapy
This focus places the sponsor within clinically relevant areas of immunotherapy and haematological immune disorders.
Haematology
The clinical landscape includes treatment interests in disorders of blood cell regulation, with emphasis on platelet disorders and patient outcomes in haematological disease.
- Thrombocytopenia
- Platelet response assessment
- Blood disorder treatment
Research activity in this area supports therapeutic development for patients whose platelet counts are affected by immune dysfunction.
Intravenous Immunoglobulin Therapy
The sponsor’s trial portfolio highlights intravenous immunoglobulin as a key therapeutic domain, with clinical interest in its use for immune-related blood disorders.
- IVIg treatment
- Immunoglobulin infusion
- Supportive immune therapy
This area reflects Kedrion’s involvement in plasma-derived medicinal products and their application in autoimmune haematology.
